Analysts, investors upbeat about Schering-Plough settlement

07/19/2004 | Star-Ledger (Newark, N.J.), The

Several analysts are encouraged by Schering-Plough's likely $350 million settlement with federal investigators over Medicare fraud allegations, saying it will unburden the company from the years-long probe and allow it to move ahead. The settlement comes as Schering-Plough expects to receive FDA approval, possibly this week, of its blockbuster cholesterol drug, Vytorin, which could result in sales of more than $1 billion a year.

View Full Article in:

Star-Ledger (Newark, N.J.), The

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Sr. Regulatory Specialist, Biotech Center of Expertise
BASF, The Chemical Co.
San Diego, CA
Food Lawyer
Cargill
Wayzata, MN
Director of Clinical Research
Regenesis Biomedical, Inc.
Scottsdale, AZ
Actuary
Meridian Health Plan
Detroit, MI
Assistant Vice President - Dental Director
MetLife
Bridgewater, NJ